Because AUD has a chronic, relapsing course, ongoing clinical management is required. In the absence of empirical data to guide the optimal duration of treatment, pharmacotherapy is recommended for at least 6 months, at which point its usefulness can be re-evaluated. If deemed clinically necessary, the medication can be continued indefinitely.
